ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,114.63
-0.01%
US Tech 100
21,524.40
0.41%
Dow Jones
44,546.08
-0.37%
Brent Oil
74.715
0.65%
Bitcoin
96,369.67
0.22%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Germany
  5. TG

  6. Sangamo Therapeutics Inc (GBY) Quote

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc (GBY)

TG
1.12
0.00
(0.00%)
Closed February 17 4:00PM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.12
Bid
1.12
Ask
1.12
Volume
0.00
0.00 Day's Range 0.00
0.2901 52 Week Range 3.3005
Market Cap
233.684M
Previous Close
1.12
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
49,855
Shares Outstanding
208,646,870
Dividend Yield
-
PE Ratio
-0.95
Earnings Per Share (EPS)
-1.24
Revenue
176.23M
Net Profit
-257.83M

About Sangamo Therapeutics Inc

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.sangamo.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Sangamo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GBY. The last closing price for Sangamo Therapeutics was 1.12 €. Over the last year, Sangamo Therapeutics shares have traded in a share price range of 0.2901 € to 3.3005 €.

Sangamo Therapeutics currently has 208,646,870 shares outstanding. The market capitalization of Sangamo Therapeutics is 233.68 € million. Sangamo Therapeutics has a price to earnings ratio (PE ratio) of -0.95.

Ask ADVFN Intelligence (AI)

GBY Latest News

More News
No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0356-3.08065074421.15561.15561.0502127241.09785288DE
40.06986.64635307561.05021.4431.0308185191.1366062DE
12-0.6802-37.78469058991.80023.30050.9425498551.69521845DE
260.319939.98250218720.80013.30050.6304999486111.61001986DE
52-0.23-17.0370370371.353.30050.2901420891.22830593DE
156-4.024-78.22706065325.1445.70.2722254161.16658733DE
260-5.867-83.97023042796.98715.6680.2722132141.50748046DE

GBY - Frequently Asked Questions (FAQ)

What is the current Sangamo Therapeutics share price?
The current share price of Sangamo Therapeutics is 1.12 €
How many Sangamo Therapeutics shares are in issue?
Sangamo Therapeutics has 208,646,870 shares in issue
What is the market cap of Sangamo Therapeutics?
The market capitalisation of Sangamo Therapeutics is EUR 233.68M
What is the 1 year trading range for Sangamo Therapeutics share price?
Sangamo Therapeutics has traded in the range of 0.2901 € to 3.3005 € during the past year
What is the PE ratio of Sangamo Therapeutics?
The price to earnings ratio of Sangamo Therapeutics is -0.95
What is the cash to sales ratio of Sangamo Therapeutics?
The cash to sales ratio of Sangamo Therapeutics is 1.39
What is the reporting currency for Sangamo Therapeutics?
Sangamo Therapeutics reports financial results in USD
What is the latest annual turnover for Sangamo Therapeutics?
The latest annual turnover of Sangamo Therapeutics is USD 176.23M
What is the latest annual profit for Sangamo Therapeutics?
The latest annual profit of Sangamo Therapeutics is USD -257.83M
What is the registered address of Sangamo Therapeutics?
The registered address for Sangamo Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Sangamo Therapeutics website address?
The website address for Sangamo Therapeutics is www.sangamo.com
Which industry sector does Sangamo Therapeutics operate in?
Sangamo Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
013CJDcom Inc
19.792 €
(0.00%)
0
013AJD.com Inc
39.45 €
(0.00%)
0
0110Thesis Gold Inc
0.536 €
(0.00%)
0
00WAspermont Ltd
0.0035 €
(0.00%)
0
000Greenvolt Energias Renovaveis SA
0.00 €
(0.00%)
0
013CJDcom Inc
19.792 €
(0.00%)
0
013AJD.com Inc
39.45 €
(0.00%)
0
0110Thesis Gold Inc
0.536 €
(0.00%)
0
00WAspermont Ltd
0.0035 €
(0.00%)
0
000Greenvolt Energias Renovaveis SA
0.00 €
(0.00%)
0
013CJDcom Inc
19.792 €
(0.00%)
0
013AJD.com Inc
39.45 €
(0.00%)
0
0110Thesis Gold Inc
0.536 €
(0.00%)
0
00WAspermont Ltd
0.0035 €
(0.00%)
0
000Greenvolt Energias Renovaveis SA
0.00 €
(0.00%)
0

Discussion

View Full Feed
Hoghead7 Hoghead7 4 minutes ago
Feasel speaking at NJ energy coalition in March
https://www.linkedin.com/posts/erick-ford-60530113_coming-march-11th-2025-another-great-event-activity-7297053390952357888-4QH7?utm_source=share&utm_medium=member_android&rcm=ACoAAD0kMAgBCjdlnBi58ae16C413y05wUfF-9o
FCEL
ValueX ValueX 11 minutes ago
The financial volume in the range of $200-500 per day does not tell me much. At the moment only small traders. Let's see if there will be an increase in interest in the coming days .
At the moment I am skeptical 😎
AVVH
fink fink 17 minutes ago
I had to stop reading after the first sentence,
When he used the word "raid" that said it all.

They are not raiding anything. They are auditing the department and we all know the SEC is so on the up and up.

Let's see what they find. USAID was an eye opener. I k
IGPK
newmedman newmedman 17 minutes ago
that thought did cross my mind but I'm supposed to be a libtard. My boobs aren't that much but I'll die laughing if he posts me back
ElementalArcher25 ElementalArcher25 18 minutes ago
I agree. I want the best price possible but if Naz can get an offer of 3 or more I would good with that but under 2 I would say wait but that's just mho.
ELTP
jour_trader jour_trader 23 minutes ago
Not necessarily. If R&D pipeline really is robust, we need time to execute. R&D pre-FDA filing isn't worth more than an FDA filing, which is less than an approved and launched product. R&D formulation lately has been slow to move due to all of the recent product launches, which is the reason to look
ELTP
janice shell janice shell 24 minutes ago
Yes? What "fraud" and "theft" have Musk and his proteges found? What they've bragged about finding?

Where's the proof? No one's seen any.
shurtha2000 shurtha2000 25 minutes ago
I'm expecting Fort Knox Audit to come up on a lot of missing gold -what happens to the price ? $$
Preciouslife1 Preciouslife1 26 minutes ago
https://www.mlb.com/news/giancarlo-stanton-dealing-with-sore-elbows-at-yankees-spring-training
silkmaster silkmaster 27 minutes ago
Well i hope that you will be able to change that target from 2029 back to 2025. based on news from KT and lab.

Less R&D news , yes the world of science will love it and it could help the share value years from now , but i think investors that are in Lt care less by now of what happe
KBLB
Whalatane Whalatane 27 minutes ago
Yes, the approval for a share buyback can expire, depending on the jurisdiction and the specific terms set by the company or its governing body.

United States: In the U.S., share buyback programs authorized by a company's board of directors typically do not have a statutory expiration
AMRN
ElementalArcher25 ElementalArcher25 27 minutes ago
Just remember the old saying a bird in the hand is better than 2 in the bush
ELTP
Preciouslife1 Preciouslife1 29 minutes ago
https://www.mlb.com/news/starling-marte-ready-to-contribute-for-mets-in-2025
jour_trader jour_trader 30 minutes ago
Likely the same result as Adderall IR & ER that were already crowded when Elite entered the market. We earned significant marketshare...
ELTP
jealmc79 jealmc79 33 minutes ago
" style="caret-color: rgb(29, 38, 46); color: rgba(29, 38, 46, 1); font-family: DMSans-Regular, sans-serif; font-size: 15px".i think they were built in Lam Dong..."
style="caret-color: rgb(29, 38, 46); color: rgba(29, 38, 46, 1); font-family: DMSans-Regular, sans-serif; font-size: 15p
KBLB
ElementalArcher25 ElementalArcher25 34 minutes ago
Yeah great ideal and what happens if 10 other generic drug makers get approved to manufacture Vyvanse over the next year?
ELTP
OMOLIVES OMOLIVES 35 minutes ago
Not sure...but these expenses are just being credited to the purchase price anyhow ;)
HMBL
newmedman newmedman 38 minutes ago
oh, coho is the tastiest fish I ever had. We cut the steaks up from the whale and they just don't shrink. It's seriously good fish. There's nothing else like it in my book, but I'm a bit of a homer. Waukegan harbor and I know each other very well.
asp42001 asp42001 39 minutes ago
Government E2E EBPP&H Common Sense!

USIO could help process, handle & verify government spending!

Follow digital money-trails, cut expenses...WIN-Win!

DEAL!
USIO
getmenews getmenews 39 minutes ago
Interesting, Japan been accumulating XRP, now they want to offer ETF's, wonder if Japan will unload once it's approved, which it shouldn't be unless it's traded as a security! HMM

Robinhood didn't allow traders to buy at .50, now traders can trade it again at 2.50? HMM

XRPUSD
norisknorewards norisknorewards 43 minutes ago
Must be a sign of the bottom if ya ask me based on this posters history

Exciting
NWBO
janice shell janice shell 44 minutes ago
That would be generally helpful. Yes, his work on EVs has been interesting, but hardly problem-free. The same can be said of SpaceX.

The work can be carried on by people who are not drama queens.
arizona1 arizona1 44 minutes ago
I wouldn't be surprised if he was more attracted to yours.

Your Recent History

TG
GBY
Sangamo Therapeutics
FX
USDEUR
US Dollar vs Euro
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads